Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Michael J. Fox Foundation for Parkinson's Research (MJFF) has awarded additional funding of $1m to NeuroDerm for advancing the clinical development of its drug candidate, ND0612, for the treatment of Parkinson's disease.
Subscribe to our email newsletter
Part of the Foundation’s 2013 Therapeutic Pipeline program, the grant will support an upcoming phase 2 clinical trial with the subcutaneously delivered drug that is currently under development.
A proprietary levodopa/carbidopa liquid formula that bypasses the digestive tract, ND0612 will be continuously administered through a sub-cutaneous delivery patch that would maintain constant levodopa plasma concentrations.
With a potential to enhance the existing standard of treatment for patients with Parkinson’s disease, ND0612 was well-tolerated and safe during human trials.
MJFF CEO PhD Todd Sherer said "ND0612’s potential ability to provide steady, therapeutic levodopa levels could improve upon current symptomatic treatments for Parkinson’s patients."
"Finding such a drug remains a priority for the Foundation"
Around six million people across the globe are currently affected by the Parkinson’s disease, which is caused due to ceasing of dopaminergic brain cells that results in reduced dopamine signalling in the brain.